{'52WeekChange': 0.12003386,
 'SandP52WeekChange': 0.0644362,
 'address1': '1350 Old Bayshore Highway',
 'address2': 'Suite 400',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 13.25,
 'askSize': 800,
 'averageDailyVolume10Day': 430087,
 'averageVolume': 716595,
 'averageVolume10days': 430087,
 'beta': 1.048739,
 'beta3Year': None,
 'bid': 13.01,
 'bidSize': 2200,
 'bookValue': 3.746,
 'category': None,
 'circulatingSupply': None,
 'city': 'Burlingame',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 13.595,
 'dayLow': 13.12,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': 0.937,
 'enterpriseToEbitda': 5.048,
 'enterpriseToRevenue': 4.795,
 'enterpriseValue': 1364342144,
 'exDividendDate': 1441670400,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 13.909429,
 'fiftyTwoWeekHigh': 15.62,
 'fiftyTwoWeekLow': 7.58,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 54578170,
 'forwardEps': 1.2,
 'forwardPE': 11.041666,
 'fromCurrency': None,
 'fullTimeEmployees': 5,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.32329,
 'heldPercentInstitutions': 0.76365995,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': 1401753600,
 'lastSplitFactor': '1241:1000',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/inva.com',
 'longBusinessSummary': 'Innoviva, Inc. engages in the development and '
                        'commercialization of pharmaceuticals. The company has '
                        'long-acting beta2 agonist (LABA) collaboration '
                        'agreement with Glaxo Group Limited to develop and '
                        'commercialize once-daily products for the treatment '
                        'of chronic obstructive pulmonary disease and asthma. '
                        'Its products include RELVAR/BREO ELLIPTA, a '
                        'once-daily combination medicine consisting of a LABA, '
                        'vilanterol (VI), an inhaled corticosteroid (ICS), and '
                        'fluticasone furoate; ANORO ELLIPTA, a once-daily '
                        'medicine combining a long-acting muscarinic '
                        'antagonist (LAMA), umeclidinium bromide (UMEC), with '
                        'a LABA, and VI; and TRELEGY ELLIPTA, a once-daily '
                        'combination medicine consisting of an ICS, LAMA, and '
                        'LABA. The company was formerly known as Theravance, '
                        'Inc. and changed its name to Innoviva, Inc. in '
                        'January 2016. Innoviva, Inc. was incorporated in 1996 '
                        'and is headquartered in Burlingame, California.',
 'longName': 'Innoviva, Inc.',
 'market': 'us_market',
 'marketCap': 1342489984,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_24362',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': 188935008,
 'nextFiscalYearEnd': 1640908800,
 'open': 13.55,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': 0.53,
 'phone': '650 238 9600',
 'previousClose': 13.57,
 'priceHint': 2,
 'priceToBook': 3.5371063,
 'priceToSalesTrailing12Months': 4.718587,
 'profitMargins': 0.66406995,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 13.595,
 'regularMarketDayLow': 13.12,
 'regularMarketOpen': 13.55,
 'regularMarketPreviousClose': 13.57,
 'regularMarketPrice': 13.55,
 'regularMarketVolume': 353240,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 101320000,
 'sharesPercentSharesOut': 0.12060001,
 'sharesShort': 12219140,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 12645846,
 'shortName': 'Innoviva, Inc.',
 'shortPercentOfFloat': 0.21219999,
 'shortRatio': 15.56,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'INVA',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': 0,
 'trailingAnnualDividendYield': 0,
 'trailingEps': 1.663,
 'trailingPE': 7.967529,
 'twoHundredDayAverage': 13.456403,
 'volume': 353240,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.inva.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '94010'}